Clinical Trial Update: CD276-targeted Chimeric Antigen Receptor T Cells in Treatment With Advanced Pancreatic Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating CD276-targeted CAR-T cells in advanced pancreatic carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Carcinoma

Drugs mentioned

• CD276-targeted chimeric antigen receptor T cells (CD276-targeted CAR-T cells)

Snippet

Sponsor: Shenzhen University General Hospital | Conditions: Advanced Pancreatic Carcinoma | Phase 1, Phase 2 | Status: UNKNOWN